Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study

• Zimu Gong,
• Godsfavour Umoru,
• Jorge Monge,
• Nishi Shah,
• Ghulam Rehman Mohyuddin,
• Sabarinath Venniyil Radhakrishnan,
• Rajshekhar Chakraborty,
• Leo Rasche,
• Carolina Schinke,
• Anita D’Souza,
• Meera Mohan

Affiliations

Zimu Gong

Division of Hematology Oncology, Houston Methodist Hospital

Godsfavour Umoru

Division of Hematology Oncology, Houston Methodist Hospital

Jorge Monge

Division of Hematology/Oncology, Weill Cornell Medicine

Nishi Shah

Division of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine

Ghulam Rehman Mohyuddin

Division of Hematology/Oncology, University of Utah

Sabarinath Venniyil Radhakrishnan

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin

Rajshekhar Chakraborty

Multiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center

Leo Rasche

Department of Internal Medicine II, University Hospital of Würzburg

Carolina Schinke

Myeloma Center, University of Arkansas for Medical Science

Anita D’Souza

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin

Meera Mohan

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin